Lawsuit Filed Against Aldeyra Therapeutics Over Clinical Trial Inconsistencies

Gainey McKenna & Egleston announces a securities class action lawsuit on behalf of shareholders.

Mar. 31, 2026 at 4:45pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life of a single polished metal syringe on a clean white background, conceptually representing the abstract issues of pharmaceutical risk and clinical trial transparency at the center of this legal case.A stark, minimalist image symbolizes the high stakes and transparency issues at the heart of this class action lawsuit against a pharmaceutical company.NYC Today

A securities class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) in the United States District Court for the District of Massachusetts. The lawsuit alleges that the company failed to disclose to investors that the results of its reproxalap clinical trials were inconsistent, rendering any positive findings unreliable. The lawsuit further alleges that when news of these alleged failures became known, Aldeyra's stock price dropped significantly, harming investors.

Why it matters

This lawsuit highlights the importance of pharmaceutical companies being transparent about the results of their clinical trials, as inconsistent findings can have a major impact on investor confidence and stock prices. The case also underscores the legal risks companies face if they are perceived to have withheld material information from shareholders.

The details

The class action lawsuit was filed by Gainey McKenna & Egleston on behalf of all persons or entities who purchased or acquired Aldeyra Therapeutics securities between November 3, 2023 and March 16, 2026. The complaint alleges that Aldeyra failed to disclose that the results of its reproxalap clinical trials were inconsistent, rendering any positive findings unreliable. As a result, the company's statements about its business, operations, and prospects were allegedly false and misleading. When news of these issues became known, Aldeyra's stock price dropped by $2.99 per share, or approximately 70.7%, to close at $1.24 per share on March 17, 2026.

  • The class period covers purchases or acquisitions of Aldeyra securities between November 3, 2023 and March 16, 2026.
  • The lawsuit was filed on March 31, 2026.
  • The lead plaintiff motion deadline is set for May 29, 2026.

The players

Gainey McKenna & Egleston

A law firm that filed the securities class action lawsuit against Aldeyra Therapeutics.

Aldeyra Therapeutics, Inc.

A biopharmaceutical company that is the defendant in the class action lawsuit.

Got photos? Submit your photos here. ›

What they’re saying

“Investors who purchased or otherwise acquired shares of Aldeyra should contact the Firm prior to the May 29, 2026 lead plaintiff motion deadline.”

— Thomas J. McKenna, Attorney, Gainey McKenna & Egleston

“A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.”

— Gregory M. Egleston, Attorney, Gainey McKenna & Egleston

What’s next

The judge will set a deadline for investors to file as lead plaintiffs in the class action lawsuit.

The takeaway

This case highlights the importance of pharmaceutical companies being transparent about their clinical trial results, as inconsistencies can significantly impact investor confidence and stock prices. It also underscores the legal risks companies face if they are perceived to have withheld material information from shareholders.